December 14, 2021
Update on Novartis Agreement
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize…
Oral poster highlights data from 14 heavily pre-treated patients enrolled in pilot stage of multicenter, open-label, single arm CHARIOT study…
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies…
– Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – – Workforce reduction of approximately…
5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900…
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253…
Not for distribution by US newswire or in United StatesNESS-ZIONA, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) — VAXIL BIO LTD.…
FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its…
CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential…